A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic
BackgroundThe COVID-19 pandemic raised concern amongst clinicians that disease-modifying therapies (DMT), particularly anti-CD20 monoclonal antibodies (mAb) and fingolimod, could worsen COVID-19 in people with multiple sclerosis (pwMS). This study aimed to examine DMT prescribing trends pre- and pos...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Lal, Anoushka P Foong, Yi Chao Sanfilippo, Paul G Spelman, Tim Rath, Louise Levitz, David Fabis-Pedrini, Marzena Foschi, Matteo Habek, Mario Kalincik, Tomas Roos, Izanne Lechner-Scott, Jeannette John, Nevin Soysal, Aysun D’Amico, Emanuele Gouider, Riadh Mrabet, Saloua Gross-Paju, Katrin Cárdenas-Robledo, Simón Moghadasi, Abdorreza Naser Sa, Maria Jose Gray, Orla Oh, Jiwon Reddel, Stephen Ramanathan, Sudarshini Al-Harbi, Talal Altintas, Ayse Hardy, Todd A Ozakbas, Serkan Alroughani, Raed Kermode, Allan G Surcinelli, Andrea Laureys, Guy Eichau, Sara Prat, Alexandre Girard, Marc Duquette, Pierre Hodgkinson, Suzanne Ramo-Tello, Cristina Maimone, Davide McCombe, Pamela Spitaleri, Daniele Sanchez-Menoyo, Jose Luis Yetkin, Mehmet Fatih Baghbanian, Seyed Mohammad Karabudak, Rana Al-Asmi, Abdullah Jakob, Gregor Brecl Khoury, Samia J Etemadifar, Masoud van Pesch, Vincent Buzzard, Katherine Taylor, Bruce Butzkueven, Helmut Van der Walt, Anneke |
| description | BackgroundThe COVID-19 pandemic raised concern amongst clinicians that disease-modifying therapies (DMT), particularly anti-CD20 monoclonal antibodies (mAb) and fingolimod, could worsen COVID-19 in people with multiple sclerosis (pwMS). This study aimed to examine DMT prescribing trends pre- and post-pandemic onset.MethodsA multi-centre longitudinal study with 8,771 participants from MSBase was conducted. Two time periods were defined: pre-pandemic (March 11 2018-March 10 2020) and post-pandemic onset (March 11 2020-11 March 2022). The association between time and prescribing trends was analysed using multivariable mixed-effects logistic regression. DMT initiation refers to first initiation of any DMT, whilst DMT switches indicate changing regimen within 6 months of last use.ResultsPost-pandemic onset, there was a significant increase in DMT initiation/switching to natalizumab and cladribine [(Natalizumab-initiation: OR 1.72, 95% CI 1.39-2.13; switching: OR 1.66, 95% CI 1.40-1.98), (Cladribine-initiation: OR 1.43, 95% CI 1.09-1.87; switching: OR 1.67, 95% CI 1.41-1.98)]. Anti-CD20mAb initiation/switching decreased in the year of the pandemic, but recovered in the second year, such that overall odds increased slightly post-pandemic (initiation: OR 1.26, 95% CI 1.06-1.49; Switching: OR 1.15, 95% CI 1.02-1.29. Initiation/switching of fingolimod, interferon-beta, and alemtuzumab significantly decreased [(Fingolimod-initiation: OR 0.55, 95% CI 0.41-0.73; switching: OR 0.49, 95% CI 0.41-0.58), (Interferon-gamma-initiation: OR 0.48, 95% CI 0.41-0.57; switching: OR 0.78, 95% CI 0.62-0.99), (Alemtuzumab-initiation: OR 0.27, 95% CI 0.15-0.48; switching: OR 0.27, 95% CI 0.17-0.44)].ConclusionsPost-pandemic onset, clinicians preferentially prescribed natalizumab and cladribine over anti-CD20 mAbs and fingolimod, likely to preserve efficacy but reduce perceived immunosuppressive risks. This could have implications for disease progression in pwMS. Our findings highlight the significance of equitable DMT access globally, and the importance of evidence-based decision-making in global health challenges. |
| format | Article |
| fullrecord | <record><control><sourceid>ghent</sourceid><recordid>TN_cdi_ghent_librecat_oai_archive_ugent_be_01J718P0F63GV3RR1VJQ2E62TH</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_archive_ugent_be_01J718P0F63GV3RR1VJQ2E62TH</sourcerecordid><originalsourceid>FETCH-ghent_librecat_oai_archive_ugent_be_01J718P0F63GV3RR1VJQ2E62TH3</originalsourceid><addsrcrecordid>eNqtjk1OwzAQhb0AifJzB1_Akp2U0i5RSSndAFWVreU402SQ40QeBylX4NQ4okdg9d6b92n0rthCLfNMqOXj5obdEn1JKdcpLNjPM-9GF1FY8DEAd71vMI41euM4JTNxk-xE6Js_cnDAyToIPSHxGgkMgej6Gs_TDMUWghkmPgQgG7Cab4OJEYJP-BguDN--l28vQm1S6Wvo0N6z67NxBA8XvWPFrjht96Jp0zbtsApgTdS9QW2CbfEb9NjMVQVaqsOTWn_I3Sp_LfPjUZWHz6xYZad9_l9_fgE8nGwE</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic</title><source>SpringerNature Journals</source><source>Ghent University Academic Bibliography</source><creator>Lal, Anoushka P ; Foong, Yi Chao ; Sanfilippo, Paul G ; Spelman, Tim ; Rath, Louise ; Levitz, David ; Fabis-Pedrini, Marzena ; Foschi, Matteo ; Habek, Mario ; Kalincik, Tomas ; Roos, Izanne ; Lechner-Scott, Jeannette ; John, Nevin ; Soysal, Aysun ; D’Amico, Emanuele ; Gouider, Riadh ; Mrabet, Saloua ; Gross-Paju, Katrin ; Cárdenas-Robledo, Simón ; Moghadasi, Abdorreza Naser ; Sa, Maria Jose ; Gray, Orla ; Oh, Jiwon ; Reddel, Stephen ; Ramanathan, Sudarshini ; Al-Harbi, Talal ; Altintas, Ayse ; Hardy, Todd A ; Ozakbas, Serkan ; Alroughani, Raed ; Kermode, Allan G ; Surcinelli, Andrea ; Laureys, Guy ; Eichau, Sara ; Prat, Alexandre ; Girard, Marc ; Duquette, Pierre ; Hodgkinson, Suzanne ; Ramo-Tello, Cristina ; Maimone, Davide ; McCombe, Pamela ; Spitaleri, Daniele ; Sanchez-Menoyo, Jose Luis ; Yetkin, Mehmet Fatih ; Baghbanian, Seyed Mohammad ; Karabudak, Rana ; Al-Asmi, Abdullah ; Jakob, Gregor Brecl ; Khoury, Samia J ; Etemadifar, Masoud ; van Pesch, Vincent ; Buzzard, Katherine ; Taylor, Bruce ; Butzkueven, Helmut ; Van der Walt, Anneke</creator><creatorcontrib>Lal, Anoushka P ; Foong, Yi Chao ; Sanfilippo, Paul G ; Spelman, Tim ; Rath, Louise ; Levitz, David ; Fabis-Pedrini, Marzena ; Foschi, Matteo ; Habek, Mario ; Kalincik, Tomas ; Roos, Izanne ; Lechner-Scott, Jeannette ; John, Nevin ; Soysal, Aysun ; D’Amico, Emanuele ; Gouider, Riadh ; Mrabet, Saloua ; Gross-Paju, Katrin ; Cárdenas-Robledo, Simón ; Moghadasi, Abdorreza Naser ; Sa, Maria Jose ; Gray, Orla ; Oh, Jiwon ; Reddel, Stephen ; Ramanathan, Sudarshini ; Al-Harbi, Talal ; Altintas, Ayse ; Hardy, Todd A ; Ozakbas, Serkan ; Alroughani, Raed ; Kermode, Allan G ; Surcinelli, Andrea ; Laureys, Guy ; Eichau, Sara ; Prat, Alexandre ; Girard, Marc ; Duquette, Pierre ; Hodgkinson, Suzanne ; Ramo-Tello, Cristina ; Maimone, Davide ; McCombe, Pamela ; Spitaleri, Daniele ; Sanchez-Menoyo, Jose Luis ; Yetkin, Mehmet Fatih ; Baghbanian, Seyed Mohammad ; Karabudak, Rana ; Al-Asmi, Abdullah ; Jakob, Gregor Brecl ; Khoury, Samia J ; Etemadifar, Masoud ; van Pesch, Vincent ; Buzzard, Katherine ; Taylor, Bruce ; Butzkueven, Helmut ; Van der Walt, Anneke</creatorcontrib><description>BackgroundThe COVID-19 pandemic raised concern amongst clinicians that disease-modifying therapies (DMT), particularly anti-CD20 monoclonal antibodies (mAb) and fingolimod, could worsen COVID-19 in people with multiple sclerosis (pwMS). This study aimed to examine DMT prescribing trends pre- and post-pandemic onset.MethodsA multi-centre longitudinal study with 8,771 participants from MSBase was conducted. Two time periods were defined: pre-pandemic (March 11 2018-March 10 2020) and post-pandemic onset (March 11 2020-11 March 2022). The association between time and prescribing trends was analysed using multivariable mixed-effects logistic regression. DMT initiation refers to first initiation of any DMT, whilst DMT switches indicate changing regimen within 6 months of last use.ResultsPost-pandemic onset, there was a significant increase in DMT initiation/switching to natalizumab and cladribine [(Natalizumab-initiation: OR 1.72, 95% CI 1.39-2.13; switching: OR 1.66, 95% CI 1.40-1.98), (Cladribine-initiation: OR 1.43, 95% CI 1.09-1.87; switching: OR 1.67, 95% CI 1.41-1.98)]. Anti-CD20mAb initiation/switching decreased in the year of the pandemic, but recovered in the second year, such that overall odds increased slightly post-pandemic (initiation: OR 1.26, 95% CI 1.06-1.49; Switching: OR 1.15, 95% CI 1.02-1.29. Initiation/switching of fingolimod, interferon-beta, and alemtuzumab significantly decreased [(Fingolimod-initiation: OR 0.55, 95% CI 0.41-0.73; switching: OR 0.49, 95% CI 0.41-0.58), (Interferon-gamma-initiation: OR 0.48, 95% CI 0.41-0.57; switching: OR 0.78, 95% CI 0.62-0.99), (Alemtuzumab-initiation: OR 0.27, 95% CI 0.15-0.48; switching: OR 0.27, 95% CI 0.17-0.44)].ConclusionsPost-pandemic onset, clinicians preferentially prescribed natalizumab and cladribine over anti-CD20 mAbs and fingolimod, likely to preserve efficacy but reduce perceived immunosuppressive risks. This could have implications for disease progression in pwMS. Our findings highlight the significance of equitable DMT access globally, and the importance of evidence-based decision-making in global health challenges.</description><identifier>ISSN: 1432-1459</identifier><identifier>ISSN: 0340-5354</identifier><language>eng</language><subject>Anti-CD20 monoclonal antibodies ; Cladribine ; COVID-19 ; Disease-modifying therapy ; Medicine and Health Sciences ; Multiple sclerosis ; Natalizumab</subject><creationdate>2024</creationdate><rights>Creative Commons Attribution 4.0 International Public License (CC-BY 4.0) info:eu-repo/semantics/openAccess</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,316,782,786,4026,27867</link.rule.ids></links><search><creatorcontrib>Lal, Anoushka P</creatorcontrib><creatorcontrib>Foong, Yi Chao</creatorcontrib><creatorcontrib>Sanfilippo, Paul G</creatorcontrib><creatorcontrib>Spelman, Tim</creatorcontrib><creatorcontrib>Rath, Louise</creatorcontrib><creatorcontrib>Levitz, David</creatorcontrib><creatorcontrib>Fabis-Pedrini, Marzena</creatorcontrib><creatorcontrib>Foschi, Matteo</creatorcontrib><creatorcontrib>Habek, Mario</creatorcontrib><creatorcontrib>Kalincik, Tomas</creatorcontrib><creatorcontrib>Roos, Izanne</creatorcontrib><creatorcontrib>Lechner-Scott, Jeannette</creatorcontrib><creatorcontrib>John, Nevin</creatorcontrib><creatorcontrib>Soysal, Aysun</creatorcontrib><creatorcontrib>D’Amico, Emanuele</creatorcontrib><creatorcontrib>Gouider, Riadh</creatorcontrib><creatorcontrib>Mrabet, Saloua</creatorcontrib><creatorcontrib>Gross-Paju, Katrin</creatorcontrib><creatorcontrib>Cárdenas-Robledo, Simón</creatorcontrib><creatorcontrib>Moghadasi, Abdorreza Naser</creatorcontrib><creatorcontrib>Sa, Maria Jose</creatorcontrib><creatorcontrib>Gray, Orla</creatorcontrib><creatorcontrib>Oh, Jiwon</creatorcontrib><creatorcontrib>Reddel, Stephen</creatorcontrib><creatorcontrib>Ramanathan, Sudarshini</creatorcontrib><creatorcontrib>Al-Harbi, Talal</creatorcontrib><creatorcontrib>Altintas, Ayse</creatorcontrib><creatorcontrib>Hardy, Todd A</creatorcontrib><creatorcontrib>Ozakbas, Serkan</creatorcontrib><creatorcontrib>Alroughani, Raed</creatorcontrib><creatorcontrib>Kermode, Allan G</creatorcontrib><creatorcontrib>Surcinelli, Andrea</creatorcontrib><creatorcontrib>Laureys, Guy</creatorcontrib><creatorcontrib>Eichau, Sara</creatorcontrib><creatorcontrib>Prat, Alexandre</creatorcontrib><creatorcontrib>Girard, Marc</creatorcontrib><creatorcontrib>Duquette, Pierre</creatorcontrib><creatorcontrib>Hodgkinson, Suzanne</creatorcontrib><creatorcontrib>Ramo-Tello, Cristina</creatorcontrib><creatorcontrib>Maimone, Davide</creatorcontrib><creatorcontrib>McCombe, Pamela</creatorcontrib><creatorcontrib>Spitaleri, Daniele</creatorcontrib><creatorcontrib>Sanchez-Menoyo, Jose Luis</creatorcontrib><creatorcontrib>Yetkin, Mehmet Fatih</creatorcontrib><creatorcontrib>Baghbanian, Seyed Mohammad</creatorcontrib><creatorcontrib>Karabudak, Rana</creatorcontrib><creatorcontrib>Al-Asmi, Abdullah</creatorcontrib><creatorcontrib>Jakob, Gregor Brecl</creatorcontrib><creatorcontrib>Khoury, Samia J</creatorcontrib><creatorcontrib>Etemadifar, Masoud</creatorcontrib><creatorcontrib>van Pesch, Vincent</creatorcontrib><creatorcontrib>Buzzard, Katherine</creatorcontrib><creatorcontrib>Taylor, Bruce</creatorcontrib><creatorcontrib>Butzkueven, Helmut</creatorcontrib><creatorcontrib>Van der Walt, Anneke</creatorcontrib><title>A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic</title><description>BackgroundThe COVID-19 pandemic raised concern amongst clinicians that disease-modifying therapies (DMT), particularly anti-CD20 monoclonal antibodies (mAb) and fingolimod, could worsen COVID-19 in people with multiple sclerosis (pwMS). This study aimed to examine DMT prescribing trends pre- and post-pandemic onset.MethodsA multi-centre longitudinal study with 8,771 participants from MSBase was conducted. Two time periods were defined: pre-pandemic (March 11 2018-March 10 2020) and post-pandemic onset (March 11 2020-11 March 2022). The association between time and prescribing trends was analysed using multivariable mixed-effects logistic regression. DMT initiation refers to first initiation of any DMT, whilst DMT switches indicate changing regimen within 6 months of last use.ResultsPost-pandemic onset, there was a significant increase in DMT initiation/switching to natalizumab and cladribine [(Natalizumab-initiation: OR 1.72, 95% CI 1.39-2.13; switching: OR 1.66, 95% CI 1.40-1.98), (Cladribine-initiation: OR 1.43, 95% CI 1.09-1.87; switching: OR 1.67, 95% CI 1.41-1.98)]. Anti-CD20mAb initiation/switching decreased in the year of the pandemic, but recovered in the second year, such that overall odds increased slightly post-pandemic (initiation: OR 1.26, 95% CI 1.06-1.49; Switching: OR 1.15, 95% CI 1.02-1.29. Initiation/switching of fingolimod, interferon-beta, and alemtuzumab significantly decreased [(Fingolimod-initiation: OR 0.55, 95% CI 0.41-0.73; switching: OR 0.49, 95% CI 0.41-0.58), (Interferon-gamma-initiation: OR 0.48, 95% CI 0.41-0.57; switching: OR 0.78, 95% CI 0.62-0.99), (Alemtuzumab-initiation: OR 0.27, 95% CI 0.15-0.48; switching: OR 0.27, 95% CI 0.17-0.44)].ConclusionsPost-pandemic onset, clinicians preferentially prescribed natalizumab and cladribine over anti-CD20 mAbs and fingolimod, likely to preserve efficacy but reduce perceived immunosuppressive risks. This could have implications for disease progression in pwMS. Our findings highlight the significance of equitable DMT access globally, and the importance of evidence-based decision-making in global health challenges.</description><subject>Anti-CD20 monoclonal antibodies</subject><subject>Cladribine</subject><subject>COVID-19</subject><subject>Disease-modifying therapy</subject><subject>Medicine and Health Sciences</subject><subject>Multiple sclerosis</subject><subject>Natalizumab</subject><issn>1432-1459</issn><issn>0340-5354</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ADGLB</sourceid><recordid>eNqtjk1OwzAQhb0AifJzB1_Akp2U0i5RSSndAFWVreU402SQ40QeBylX4NQ4okdg9d6b92n0rthCLfNMqOXj5obdEn1JKdcpLNjPM-9GF1FY8DEAd71vMI41euM4JTNxk-xE6Js_cnDAyToIPSHxGgkMgej6Gs_TDMUWghkmPgQgG7Cab4OJEYJP-BguDN--l28vQm1S6Wvo0N6z67NxBA8XvWPFrjht96Jp0zbtsApgTdS9QW2CbfEb9NjMVQVaqsOTWn_I3Sp_LfPjUZWHz6xYZad9_l9_fgE8nGwE</recordid><startdate>2024</startdate><enddate>2024</enddate><creator>Lal, Anoushka P</creator><creator>Foong, Yi Chao</creator><creator>Sanfilippo, Paul G</creator><creator>Spelman, Tim</creator><creator>Rath, Louise</creator><creator>Levitz, David</creator><creator>Fabis-Pedrini, Marzena</creator><creator>Foschi, Matteo</creator><creator>Habek, Mario</creator><creator>Kalincik, Tomas</creator><creator>Roos, Izanne</creator><creator>Lechner-Scott, Jeannette</creator><creator>John, Nevin</creator><creator>Soysal, Aysun</creator><creator>D’Amico, Emanuele</creator><creator>Gouider, Riadh</creator><creator>Mrabet, Saloua</creator><creator>Gross-Paju, Katrin</creator><creator>Cárdenas-Robledo, Simón</creator><creator>Moghadasi, Abdorreza Naser</creator><creator>Sa, Maria Jose</creator><creator>Gray, Orla</creator><creator>Oh, Jiwon</creator><creator>Reddel, Stephen</creator><creator>Ramanathan, Sudarshini</creator><creator>Al-Harbi, Talal</creator><creator>Altintas, Ayse</creator><creator>Hardy, Todd A</creator><creator>Ozakbas, Serkan</creator><creator>Alroughani, Raed</creator><creator>Kermode, Allan G</creator><creator>Surcinelli, Andrea</creator><creator>Laureys, Guy</creator><creator>Eichau, Sara</creator><creator>Prat, Alexandre</creator><creator>Girard, Marc</creator><creator>Duquette, Pierre</creator><creator>Hodgkinson, Suzanne</creator><creator>Ramo-Tello, Cristina</creator><creator>Maimone, Davide</creator><creator>McCombe, Pamela</creator><creator>Spitaleri, Daniele</creator><creator>Sanchez-Menoyo, Jose Luis</creator><creator>Yetkin, Mehmet Fatih</creator><creator>Baghbanian, Seyed Mohammad</creator><creator>Karabudak, Rana</creator><creator>Al-Asmi, Abdullah</creator><creator>Jakob, Gregor Brecl</creator><creator>Khoury, Samia J</creator><creator>Etemadifar, Masoud</creator><creator>van Pesch, Vincent</creator><creator>Buzzard, Katherine</creator><creator>Taylor, Bruce</creator><creator>Butzkueven, Helmut</creator><creator>Van der Walt, Anneke</creator><scope>ADGLB</scope></search><sort><creationdate>2024</creationdate><title>A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic</title><author>Lal, Anoushka P ; Foong, Yi Chao ; Sanfilippo, Paul G ; Spelman, Tim ; Rath, Louise ; Levitz, David ; Fabis-Pedrini, Marzena ; Foschi, Matteo ; Habek, Mario ; Kalincik, Tomas ; Roos, Izanne ; Lechner-Scott, Jeannette ; John, Nevin ; Soysal, Aysun ; D’Amico, Emanuele ; Gouider, Riadh ; Mrabet, Saloua ; Gross-Paju, Katrin ; Cárdenas-Robledo, Simón ; Moghadasi, Abdorreza Naser ; Sa, Maria Jose ; Gray, Orla ; Oh, Jiwon ; Reddel, Stephen ; Ramanathan, Sudarshini ; Al-Harbi, Talal ; Altintas, Ayse ; Hardy, Todd A ; Ozakbas, Serkan ; Alroughani, Raed ; Kermode, Allan G ; Surcinelli, Andrea ; Laureys, Guy ; Eichau, Sara ; Prat, Alexandre ; Girard, Marc ; Duquette, Pierre ; Hodgkinson, Suzanne ; Ramo-Tello, Cristina ; Maimone, Davide ; McCombe, Pamela ; Spitaleri, Daniele ; Sanchez-Menoyo, Jose Luis ; Yetkin, Mehmet Fatih ; Baghbanian, Seyed Mohammad ; Karabudak, Rana ; Al-Asmi, Abdullah ; Jakob, Gregor Brecl ; Khoury, Samia J ; Etemadifar, Masoud ; van Pesch, Vincent ; Buzzard, Katherine ; Taylor, Bruce ; Butzkueven, Helmut ; Van der Walt, Anneke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-ghent_librecat_oai_archive_ugent_be_01J718P0F63GV3RR1VJQ2E62TH3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Anti-CD20 monoclonal antibodies</topic><topic>Cladribine</topic><topic>COVID-19</topic><topic>Disease-modifying therapy</topic><topic>Medicine and Health Sciences</topic><topic>Multiple sclerosis</topic><topic>Natalizumab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lal, Anoushka P</creatorcontrib><creatorcontrib>Foong, Yi Chao</creatorcontrib><creatorcontrib>Sanfilippo, Paul G</creatorcontrib><creatorcontrib>Spelman, Tim</creatorcontrib><creatorcontrib>Rath, Louise</creatorcontrib><creatorcontrib>Levitz, David</creatorcontrib><creatorcontrib>Fabis-Pedrini, Marzena</creatorcontrib><creatorcontrib>Foschi, Matteo</creatorcontrib><creatorcontrib>Habek, Mario</creatorcontrib><creatorcontrib>Kalincik, Tomas</creatorcontrib><creatorcontrib>Roos, Izanne</creatorcontrib><creatorcontrib>Lechner-Scott, Jeannette</creatorcontrib><creatorcontrib>John, Nevin</creatorcontrib><creatorcontrib>Soysal, Aysun</creatorcontrib><creatorcontrib>D’Amico, Emanuele</creatorcontrib><creatorcontrib>Gouider, Riadh</creatorcontrib><creatorcontrib>Mrabet, Saloua</creatorcontrib><creatorcontrib>Gross-Paju, Katrin</creatorcontrib><creatorcontrib>Cárdenas-Robledo, Simón</creatorcontrib><creatorcontrib>Moghadasi, Abdorreza Naser</creatorcontrib><creatorcontrib>Sa, Maria Jose</creatorcontrib><creatorcontrib>Gray, Orla</creatorcontrib><creatorcontrib>Oh, Jiwon</creatorcontrib><creatorcontrib>Reddel, Stephen</creatorcontrib><creatorcontrib>Ramanathan, Sudarshini</creatorcontrib><creatorcontrib>Al-Harbi, Talal</creatorcontrib><creatorcontrib>Altintas, Ayse</creatorcontrib><creatorcontrib>Hardy, Todd A</creatorcontrib><creatorcontrib>Ozakbas, Serkan</creatorcontrib><creatorcontrib>Alroughani, Raed</creatorcontrib><creatorcontrib>Kermode, Allan G</creatorcontrib><creatorcontrib>Surcinelli, Andrea</creatorcontrib><creatorcontrib>Laureys, Guy</creatorcontrib><creatorcontrib>Eichau, Sara</creatorcontrib><creatorcontrib>Prat, Alexandre</creatorcontrib><creatorcontrib>Girard, Marc</creatorcontrib><creatorcontrib>Duquette, Pierre</creatorcontrib><creatorcontrib>Hodgkinson, Suzanne</creatorcontrib><creatorcontrib>Ramo-Tello, Cristina</creatorcontrib><creatorcontrib>Maimone, Davide</creatorcontrib><creatorcontrib>McCombe, Pamela</creatorcontrib><creatorcontrib>Spitaleri, Daniele</creatorcontrib><creatorcontrib>Sanchez-Menoyo, Jose Luis</creatorcontrib><creatorcontrib>Yetkin, Mehmet Fatih</creatorcontrib><creatorcontrib>Baghbanian, Seyed Mohammad</creatorcontrib><creatorcontrib>Karabudak, Rana</creatorcontrib><creatorcontrib>Al-Asmi, Abdullah</creatorcontrib><creatorcontrib>Jakob, Gregor Brecl</creatorcontrib><creatorcontrib>Khoury, Samia J</creatorcontrib><creatorcontrib>Etemadifar, Masoud</creatorcontrib><creatorcontrib>van Pesch, Vincent</creatorcontrib><creatorcontrib>Buzzard, Katherine</creatorcontrib><creatorcontrib>Taylor, Bruce</creatorcontrib><creatorcontrib>Butzkueven, Helmut</creatorcontrib><creatorcontrib>Van der Walt, Anneke</creatorcontrib><collection>Ghent University Academic Bibliography</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lal, Anoushka P</au><au>Foong, Yi Chao</au><au>Sanfilippo, Paul G</au><au>Spelman, Tim</au><au>Rath, Louise</au><au>Levitz, David</au><au>Fabis-Pedrini, Marzena</au><au>Foschi, Matteo</au><au>Habek, Mario</au><au>Kalincik, Tomas</au><au>Roos, Izanne</au><au>Lechner-Scott, Jeannette</au><au>John, Nevin</au><au>Soysal, Aysun</au><au>D’Amico, Emanuele</au><au>Gouider, Riadh</au><au>Mrabet, Saloua</au><au>Gross-Paju, Katrin</au><au>Cárdenas-Robledo, Simón</au><au>Moghadasi, Abdorreza Naser</au><au>Sa, Maria Jose</au><au>Gray, Orla</au><au>Oh, Jiwon</au><au>Reddel, Stephen</au><au>Ramanathan, Sudarshini</au><au>Al-Harbi, Talal</au><au>Altintas, Ayse</au><au>Hardy, Todd A</au><au>Ozakbas, Serkan</au><au>Alroughani, Raed</au><au>Kermode, Allan G</au><au>Surcinelli, Andrea</au><au>Laureys, Guy</au><au>Eichau, Sara</au><au>Prat, Alexandre</au><au>Girard, Marc</au><au>Duquette, Pierre</au><au>Hodgkinson, Suzanne</au><au>Ramo-Tello, Cristina</au><au>Maimone, Davide</au><au>McCombe, Pamela</au><au>Spitaleri, Daniele</au><au>Sanchez-Menoyo, Jose Luis</au><au>Yetkin, Mehmet Fatih</au><au>Baghbanian, Seyed Mohammad</au><au>Karabudak, Rana</au><au>Al-Asmi, Abdullah</au><au>Jakob, Gregor Brecl</au><au>Khoury, Samia J</au><au>Etemadifar, Masoud</au><au>van Pesch, Vincent</au><au>Buzzard, Katherine</au><au>Taylor, Bruce</au><au>Butzkueven, Helmut</au><au>Van der Walt, Anneke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic</atitle><date>2024</date><risdate>2024</risdate><issn>1432-1459</issn><issn>0340-5354</issn><abstract>BackgroundThe COVID-19 pandemic raised concern amongst clinicians that disease-modifying therapies (DMT), particularly anti-CD20 monoclonal antibodies (mAb) and fingolimod, could worsen COVID-19 in people with multiple sclerosis (pwMS). This study aimed to examine DMT prescribing trends pre- and post-pandemic onset.MethodsA multi-centre longitudinal study with 8,771 participants from MSBase was conducted. Two time periods were defined: pre-pandemic (March 11 2018-March 10 2020) and post-pandemic onset (March 11 2020-11 March 2022). The association between time and prescribing trends was analysed using multivariable mixed-effects logistic regression. DMT initiation refers to first initiation of any DMT, whilst DMT switches indicate changing regimen within 6 months of last use.ResultsPost-pandemic onset, there was a significant increase in DMT initiation/switching to natalizumab and cladribine [(Natalizumab-initiation: OR 1.72, 95% CI 1.39-2.13; switching: OR 1.66, 95% CI 1.40-1.98), (Cladribine-initiation: OR 1.43, 95% CI 1.09-1.87; switching: OR 1.67, 95% CI 1.41-1.98)]. Anti-CD20mAb initiation/switching decreased in the year of the pandemic, but recovered in the second year, such that overall odds increased slightly post-pandemic (initiation: OR 1.26, 95% CI 1.06-1.49; Switching: OR 1.15, 95% CI 1.02-1.29. Initiation/switching of fingolimod, interferon-beta, and alemtuzumab significantly decreased [(Fingolimod-initiation: OR 0.55, 95% CI 0.41-0.73; switching: OR 0.49, 95% CI 0.41-0.58), (Interferon-gamma-initiation: OR 0.48, 95% CI 0.41-0.57; switching: OR 0.78, 95% CI 0.62-0.99), (Alemtuzumab-initiation: OR 0.27, 95% CI 0.15-0.48; switching: OR 0.27, 95% CI 0.17-0.44)].ConclusionsPost-pandemic onset, clinicians preferentially prescribed natalizumab and cladribine over anti-CD20 mAbs and fingolimod, likely to preserve efficacy but reduce perceived immunosuppressive risks. This could have implications for disease progression in pwMS. Our findings highlight the significance of equitable DMT access globally, and the importance of evidence-based decision-making in global health challenges.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1432-1459 |
| ispartof | |
| issn | 1432-1459 0340-5354 |
| language | eng |
| recordid | cdi_ghent_librecat_oai_archive_ugent_be_01J718P0F63GV3RR1VJQ2E62TH |
| source | SpringerNature Journals; Ghent University Academic Bibliography |
| subjects | Anti-CD20 monoclonal antibodies Cladribine COVID-19 Disease-modifying therapy Medicine and Health Sciences Multiple sclerosis Natalizumab |
| title | A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T14%3A09%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-ghent&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20multi-centre%20longitudinal%20study%20analysing%20multiple%20sclerosis%20disease-modifying%20therapy%20prescribing%20patterns%20during%20the%20COVID-19%20pandemic&rft.au=Lal,%20Anoushka%20P&rft.date=2024&rft.issn=1432-1459&rft_id=info:doi/&rft_dat=%3Cghent%3Eoai_archive_ugent_be_01J718P0F63GV3RR1VJQ2E62TH%3C/ghent%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |